Fundraising Fox
/Companies
Sign in

Foghorn Therapeutics

NASDAQ: FHTX

Incorporated in Delaware · 4 known investors

Find your way into Foghorn Therapeutics

Sign up to see every warm intro you have to Foghorn Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Foghorn Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Foghorn Therapeutics is a clinical-stage biotech developing chromatin-targeted cancer drugs via its Gene Traffic Control platform, including a candidate co-developed with Eli Lilly.

Founders & leadership

AGAdrian Gottschalk
Adrian GottschalkPresident and Chief Executive Officer

Investors · 4

Xeraya Capitallisted by Xeraya CapitalKuala Lumpur

How we know: Xeraya Capital's portfolio page · Not right? Tell us

Biotechnology Value FundreportedSan Francisco

How we know: funding news · globenewswire.com · Not right? Tell us

Deerfield Management CompanyreportedNew York

How we know: funding news · globenewswire.com · Not right? Tell us

Funding

SEC filings, press & company announcements

$42M disclosed across 1 of 3 rounds · 2020–2026

Source: company announcements and press reports — follow each round's link for the claim.

Valuation · disclosed

Disclosed events
$451.1Mvaluation at IPOOct 2020 · $16.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

In the news

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026globenewswire.com · Jan 2026Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipelineglobenewswire.com · May 2024

Frequently asked questions

What does Foghorn Therapeutics do?
Foghorn Therapeutics is a clinical-stage biotech developing chromatin-targeted cancer drugs via its Gene Traffic Control platform, including a candidate co-developed with Eli Lilly.
Who are Foghorn Therapeutics's investors?
Foghorn Therapeutics's investors include Flagship Pioneering, Xeraya Capital, Biotechnology Value Fund, Deerfield Management Company.
How much funding has Foghorn Therapeutics raised?
Foghorn Therapeutics has disclosed $42M raised across 1 of its 3 known rounds.